Zobrazeno 1 - 10
of 75
pro vyhledávání: '"Rita Assi"'
Autor:
Vincent M DeStefano, Masayuki Wada, Kevin G Pinz, Rita Assi, Hongyu Zhang, Weijia Wang, Wenli Zhang, Darshi Shah, Yupo Ma, Huda Salman
Publikováno v:
Clinical and Translational Medicine, Vol 14, Iss 7, Pp n/a-n/a (2024)
Externí odkaz:
https://doaj.org/article/8fb761cae8624f079298769fd2e6285b
Autor:
Robert Emmons, Lionel Apetoh, Rita Assi, Nabil Hagag, Sherif Farag, Allie Carter, Magdalena Czader, Rafat Abonnour, Yupo Ma, Huda Salman
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/eb11de965e514a4aa3aede75b2a91a8e
Autor:
Musa Yilmaz, Mansour Alfayez, Courtney D. DiNardo, Gautam Borthakur, Tapan M. Kadia, Marina Y. Konopleva, Sanam Loghavi, Rashmi Kanagal-Shamanna, Keyur P. Patel, Elias J. Jabbour, Guillermo Garcia-Manero, Naveen Pemmaraju, Sherry A. Pierce, Issa Ghayas, Nicholas J. Short, Guillermo Montalban-Bravo, Koichi Takahashi, Rita Assi, Ahmad S. Alotaibi, Maro Ohanian, Michael Andreeff, Jorge E. Cortes, Hagop M. Kantarjian, Farhad Ravandi, Naval G. Daver
Publikováno v:
Journal of Hematology & Oncology, Vol 13, Iss 1, Pp 1-12 (2020)
Abstract Background Second-generation FLT3-inhibitors (FLT3i) demonstrated single-agent composite CR rates (CRc) of 45–55% in patients with relapsed/refractory (R/R) FLT3-mutated AML in phase II/III trials. However, > 85% of patients treated were p
Externí odkaz:
https://doaj.org/article/7f93c4d49f714de3a3a0ebfafee5e7e2
Autor:
Rita Assi, Huda Salman
Publikováno v:
Cells, Vol 11, Iss 24, p 3971 (2022)
Historical standard of care treatments of T-cell malignancies generally entailed the use of cytotoxic and depleting approaches. These strategies are, however, poorly validated and record dismal long-term outcomes. More recently, the introduction and
Externí odkaz:
https://doaj.org/article/dc2180fa15dd4891be76bf51f6eff5d4
Publikováno v:
Clinical Hematology International, Vol 3, Iss 1 (2021)
Diffuse large B-cell lymphoma (DLBCL) is a biologically and clinically heterogeneous disease. Despite good responses to standard of care frontline chemoimmunotherapy, the prognosis of relapsed/refractory (R/R) patients remains obscured by the possibl
Externí odkaz:
https://doaj.org/article/af23918698aa49269f6edb68f99ef7a2
Autor:
Musa Yilmaz, Mansour Alfayez, Courtney D. DiNardo, Gautam Borthakur, Tapan M. Kadia, Marina Y. Konopleva, Sanam Loghavi, Rashmi Kanagal-Shamanna, Keyur P. Patel, Elias J. Jabbour, Guillermo Garcia‑Manero, Naveen Pemmaraju, Sherry A. Pierce, Issa Ghayas, Nicholas J. Short, Guillermo Montalban-Bravo, Koichi Takahashi, Rita Assi, Ahmad S. Alotaibi, Maro Ohanian, Michael Andreeff, Jorge E. Cortes, Hagop M. Kantarjian, Farhad Ravandi, Naval G. Daver
Publikováno v:
Journal of Hematology & Oncology, Vol 14, Iss 1, Pp 1-2 (2021)
An amendment to this paper has been published and can be accessed via the original article.
Externí odkaz:
https://doaj.org/article/d313c571a89743b1b7d88d1fb057f169
Publikováno v:
Case Reports in Medicine, Vol 2014 (2014)
Introduction. Sunitinib malate is an oral multitargeting tyrosine kinase inhibitor approved for the first line treatment of metastatic renal cell carcinoma. Sunitinib administration is associated with several adverse events including fatigue, diarrhe
Externí odkaz:
https://doaj.org/article/c75338f7a59242b0a5fdc05bf9ea2ad1
Autor:
Daniel A. Pollyea, Jessica K. Altman, Rita Assi, Dale Bixby, Amir T. Fathi, James M. Foran, Ivana Gojo, Aric C. Hall, Brian A. Jonas, Ashwin Kishtagari, Jeffrey Lancet, Lori Maness, James Mangan, Gabriel Mannis, Guido Marcucci, Alice Mims, Kelsey Moriarty, Moaath Mustafa Ali, Jadee Neff, Reza Nejati, Rebecca Olin, Mary-Elizabeth Percival, Alexander Perl, Amanda Przespolewski, Dinesh Rao, Farhad Ravandi, Rory Shallis, Paul J. Shami, Eytan Stein, Richard M. Stone, Kendra Sweet, Swapna Thota, Geoffrey Uy, Pankit Vachhani, Carly J. Cassara, Deborah A. Freedman-Cass, Katie Stehman
Publikováno v:
Journal of the National Comprehensive Cancer Network. 21:503-513
Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy characterized by the clonal expansion of myeloid blasts in the peripheral blood, bone marrow, and/or other tissues. It is the most common form of acute leukemia among adults and a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c2bfdc5ec6e73de65bd498c0aa50af4b
https://doi.org/10.6004/jnccn.2023.0025
https://doi.org/10.6004/jnccn.2023.0025
Autor:
Khalil Diab, Christy Costanian, Marvi Bikak, Nawar Al Nasrallah, Ahmad A. Al-Hader, Edmond Bendaly, Chen Zhang, Rita Assi
Publikováno v:
Southern Medical Journal. 116:202-207
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::216e216ed686e5b713c2c91ff4e2672c
https://doi.org/10.14423/smj.0000000000001509
https://doi.org/10.14423/smj.0000000000001509
Publikováno v:
Journal of Blood Medicine
Relapse rates following allogeneic stem cell transplantation for acute myeloid leukemia remain unacceptably high and a major cause of death. Maintenance therapies post-transplant administered either to patients with impending relapse or at high risk
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bb575c06d4bf837e9d170502eb8e8e97
http://europepmc.org/articles/PMC7847363
http://europepmc.org/articles/PMC7847363